Including, but not limited to, solid tumors (liver cancer, lung cancer, stomach cancer, esophageal cancer, nasopharyngeal cancer, breast cancer, pancreatic cancer, adrenal cancer, bladder cancer, uterine cancer, ovarian cancer, etc.) and hematologic malignancies (acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, etc.)
Conditions
Interventions
Observation group:None
Sponsors
Huzhou Center Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Individuals who voluntarily participate and sign an informed consent form; 2. Individuals aged 18 to 75 (inclusive) on the date of signing the informed consent form; both men and women are eligible; 3. Individuals who have been currently or previously diagnosed with a specified cancer at a Grade II-A or higher hospital and can provide relevant medical records, including but not limited to solid tumors (liver cancer, lung cancer, stomach cancer, esophageal cancer, nasopharyngeal cancer, breast cancer, pancreatic cancer, adrenal cancer, bladder cancer, uterine cancer, ovarian cancer, etc.), hematologic malignancies (acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, etc.); 4. Be able to communicate effectively with the investigator and understand and comply with all requirements of this study.
Exclusion criteria
Exclusion criteria: 1. Study participants who tested positive for infectious diseases (based on test results for hepatitis B, hepatitis C, syphilis, or HIV obtained within 30 days prior to screening); 2. Women of childbearing potential (defined as women aged <= 54 who have not undergone hysterectomy or bilateral oophorectomy and who do not have medically confirmed ovarian failure, including women with amenorrhea of any duration) with a positive urine pregnancy test; 3. Study participants with severe or unstable cardiovascular, cerebrovascular, hepatic, renal, gastrointestinal, immune system, hematological, endocrine, metabolic, or psychiatric/psychological conditions within 1 month prior to sample collection that would interfere with blood collection; 4. Study participants deemed ineligible for participation by the investigator for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sample pass rate; | — |
Countries
China
Contacts
Public ContactMinmin Shen
Huzhou Center Hospital
Outcome results
None listed